Li Zilong, Li Jichen, Wu Meng, Li Zexin, Zhou Jiawen, Lu Yunjie, Xu Yong, Qin Lei, Fan Zhiwen
State Key Laboratory of Natural Medicines, Department of Pharmacology, China Pharmaceutical University, Nanjing, China; Institute of Brain Science and Brain-inspired Research, Shandong First Medical University, Jinan, China.
State Key Laboratory of Natural Medicines, Department of Pharmacology, China Pharmaceutical University, Nanjing, China.
Redox Biol. 2024 Dec;78:103414. doi: 10.1016/j.redox.2024.103414. Epub 2024 Oct 31.
Liver ischemia-reperfusion (I/R) injury is a clinically relevant pathophysiological process that determines the effectiveness of life-saving liver transplantation, to which aberrant ROS accumulation plays a key role. In the present study we investigated the role of SUV39H1, a lysine methyltransferases, in this process focusing on regulatory mechanism and translational potential. We report that SUV39H1 expression was up-regulated in the liver tissues of mice subjected to ischemia-reperfusion and in hepatocytes exposed to hypoxia-reoxygenation (H/R) in a redox-sensitive manner. Mechanistically, coactivator associated arginine methyltransferases 1 (CARM1) mediated redox-sensitive Suv39h1 trans-activation by promoting histone H3R17 methylation. Consistently, pharmaceutical CARM1 inhibition attenuated liver I/R injury. In addition, global or hepatocyte conditional Suv39h1 KO mice were protected from liver I/R injury. RNA-seq revealed that aldehyde dehydrogenase 1 family 1a (Aldh1a1) as a novel target for SUV39H1. SUV39H1 directly bound to the Aldh1a1 promoter and repressed Aldh1a1 transcription in H/R-challenged hepatocytes. ALDH1A1 silencing abrogated the protective effects of SUV39H1 deficiency on H/R-inflicted injuries whereas ALDH1A1 over-expression mitigated liver I/R injury in mice. Importantly, administration of a small-molecule SUV39H1 inhibitor achieved similar hepatoprotective effects as SUV39H1 deletion. Finally, increased Suv39h1 expression and decreased Aldh1a1 expression were observed in liver I/R specimens in humans. In conclusion, our data uncover a regulatory role for SUV39H1 in liver I/R injury and serve as proof-of-concept that targeting the SUV39H1-ALDH1A1 axis might be considered as a reasonable approach for the intervention of liver I/R injury.
肝脏缺血再灌注(I/R)损伤是一种具有临床相关性的病理生理过程,它决定了挽救生命的肝移植的有效性,其中异常的活性氧(ROS)积累起着关键作用。在本研究中,我们研究了赖氨酸甲基转移酶SUV39H1在此过程中的作用,重点关注其调控机制和转化潜力。我们报告称,在经历缺血再灌注的小鼠肝脏组织以及暴露于缺氧复氧(H/R)的肝细胞中,SUV39H1的表达以氧化还原敏感的方式上调。从机制上讲,共激活因子相关精氨酸甲基转移酶1(CARM1)通过促进组蛋白H3R17甲基化介导氧化还原敏感的Suv39h1反式激活。一致地,药物性抑制CARM1可减轻肝脏I/R损伤。此外,全身性或肝细胞条件性Suv39h1基因敲除小鼠对肝脏I/R损伤具有保护作用。RNA测序揭示醛脱氢酶1家族1a(Aldh1a1)是SUV39H1的一个新靶点。SUV39H1直接结合到Aldh1a1启动子上,并在H/R刺激的肝细胞中抑制Aldh1a1转录。沉默ALDH1A1可消除SUV39H1缺乏对H/R所致损伤的保护作用,而ALDH1A1过表达可减轻小鼠肝脏I/R损伤。重要的是,给予小分子SUV39H1抑制剂可产生与缺失SUV39H1相似的肝脏保护作用。最后,在人类肝脏I/R标本中观察到Suv39h1表达增加和Aldh1a1表达减少。总之,我们的数据揭示了SUV39H1在肝脏I/R损伤中的调控作用,并证明靶向SUV39H1-ALDH1A1轴可能被认为是干预肝脏I/R损伤的合理方法。